How safe is tirzepatide for weight loss?

What does the clinical evidence actually tell us about tirzepatide's safety?

The reassuring starting point is that tirzepatide's safety profile has been studied rigorously. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes, following participants for 72 weeks. Side effects were common (predominantly gastrointestinal) but serious adverse events were significantly less frequent than in the weight-loss results those trials are famous for.

One misconception worth gently setting aside: some people assume that because tirzepatide is new, its safety is essentially unknown. It is newer than, say, metformin, but by the time the MHRA granted its UK licence for weight management, the tirzepatide programme had generated data across tens of thousands of participants when the diabetes trials (the SURPASS programme) are included alongside SURMOUNT. NICE reviewed that evidence base in detail before recommending tirzepatide in December 2024. The full picture of tirzepatide's side effects is well-documented, uncertainty about short-term safety is not a reasonable reason to avoid a conversation with a prescriber.

Tirzepatide carries a Black Triangle (▼) in the UK, which signals that the MHRA is collecting additional post-market data. This is routine for any newly authorised medicine and does not mean the treatment is considered unsafe. The NHS tirzepatide medicines page provides a clear summary of the confirmed safety information for patients.

Which side effects do most people actually experience?

Gastrointestinal symptoms are by far the most common: nausea tops the list, followed by diarrhoea, constipation, vomiting, indigestion and bloating. These tend to peak in the days after starting treatment or after a dose increase, then ease as the body adjusts. The titration schedule (beginning at 2.5mg, increasing slowly at the prescriber's direction) exists largely to reduce this burden. Most people find the GI effects most noticeable in the first two to four weeks.

Other reported effects include fatigue, headache, dizziness and injection-site reactions such as mild redness or itching. These are generally short-lived. If you want a thorough breakdown of what to expect, our Mounjaro side effects page covers each of these in detail, including how common they are and how long they typically last.

The full side-effect profile of Mounjaro is detailed in its Patient Information Leaflet, which is the definitive reference for what you might experience and what to do about it. A prescriber at nume can also walk through this before treatment starts, which is exactly what the consultation is for.

Injection-site rotation (between abdomen, thigh and upper arm) helps minimise localised reactions. Storage at 2–8°C in the fridge, as set out in the SmPC, keeps the medicine effective.

When does a side effect need urgent medical attention?

Most side effects with tirzepatide are manageable at home and improve without intervention. A small number of symptoms need prompt medical attention. Know these before starting treatment.

Acute pancreatitis is a rare but serious risk. In January 2026 the MHRA issued a Drug Safety Update highlighting it across GLP-1 receptor agonist medicines, including tirzepatide. The warning sign is severe, persistent stomach pain that may spread to the back (sometimes accompanied by vomiting) that does not settle quickly. Go to A&E or call 999 if this happens. Do not wait to see whether it passes.

Gallbladder problems, including gallstones, have been reported. Signs include sharp upper-right abdominal pain, especially after eating, sometimes with fever or jaundice.

Allergic reactions (swelling of the face, throat or tongue, difficulty breathing, or a rapid rash) require emergency care immediately.

Severe dehydration can follow prolonged vomiting or diarrhoea. If you cannot keep fluids down, contact a healthcare professional the same day rather than managing at home.

You can also report any suspected side effect to the MHRA directly at Yellow Card. This reporting system feeds into the ongoing safety monitoring for tirzepatide in the UK and helps protect other patients. Our team at nume aftercare, available seven days a week, is a practical first call for side effects that are worrying you but not urgent.

Who needs extra caution, and what does that mean in practice?

Tirzepatide is not suitable for everyone, and a thorough clinical assessment is the mechanism for working that out. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should not take it. A history of pancreatitis requires careful discussion. Pregnancy, breastfeeding, and actively trying to conceive are all situations where tirzepatide is not recommended, the MHRA and NHS are clear on this. The medicine is not licensed for anyone under 18.

For women using the oral contraceptive pill, the MHRA advises adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption. This is one of several practical details covered on the broader Mounjaro safety page.

If you're due surgery, tell the anaesthetic team that you take tirzepatide, NHS England guidance specifically flags this. The question of long-term safety is an active area of research; the evidence so far is broadly reassuring, but it is honest to say that follow-up data beyond two to three years is still accumulating.

Checking your eligibility and medical history is exactly what the free consultation at nume's treatment page is designed to do. Our prescribers discuss suitability, flag any concerns, and go through the side effects relevant to your health picture. Our clinical team reviews every consultation personally, it's the non-negotiable part of what we do.